United Therapeutics Strengthens Partnership with Eli Lilly

☀️Trending News

United Therapeutics ($NASDAQ:UTHR) Corporation is an American biotechnology company based in Silver Spring, Maryland, specializing in the development of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company’s focus is to develop innovative therapies for diseases that are not adequately treated by existing medicines. Recently, United Therapeutics has strengthened its partnership with Eli Lilly and Company by extending its licensing agreement. According to the Washington Business Journal, United Therapeutics and Eli Lilly have agreed to a multi-year deal, which will allow Eli Lilly to market and sell United Therapeutics’ Treprostinil Extended Release Tablets in the United States. Treprostinil is an FDA-approved medication used to treat pulmonary arterial hypertension, which can be life-threatening. This extended agreement gives both companies the opportunity to collaborate and explore new opportunities to improve the lives of patients with pulmonary arterial hypertension. The extended agreement between United Therapeutics and Eli Lilly not only benefits patients, but it also presents a lucrative growth opportunity for both companies. United Therapeutics stands to gain from increased sales of Treprostinil thanks to Eli Lilly’s expertise in marketing and distributing the medication, while Eli Lilly can benefit from a new revenue stream.

Additionally, this agreement could pave the way for further collaboration between United Therapeutics and Eli Lilly on developing new treatments for other diseases.

Stock Price

On Friday, United Therapeutics announced that it had strengthened its partnership with Eli Lilly, a leading pharmaceutical company. This news sent the stock of UNITED THERAPEUTICS up by 0.3%, with the stock opening at $240.8 and closing at $240.7, higher than its prior closing price of 240.0. The terms of the partnership agreement were not disclosed, but it is believed to be beneficial for both companies. This news has been well-received by investors, as it provides additional confidence in United Therapeutics’ ability to continue to be a successful and innovative player in the healthcare industry. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for United Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for United Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for United Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for United Therapeutics are shown below. More…

Analysis

As GoodWhale, we have analyzed UNITED THERAPEUTICS‘s financials and are pleased to report a high health score of 9/10. This means that UNITED THERAPEUTICS has solid cash flows and debt, and is likely to be able to safely ride out any crisis without facing bankruptcy. Additionally, GoodWhale has classified UNITED THERAPEUTICS as a “gorilla” company. Gorilla companies are those that have achieved stable and high revenue or earnings growth due to their strong competitive advantage. GoodWhale believes that UNITED THERAPEUTICS will be especially appealing to investors who prioritize asset, growth, and profitability. That said, dividend investors may find another company more suited to their needs. More…

Peers

The company’s main competitors are MannKind Corp, Sanofi SA, Eli Lilly and Co.

– MannKind Corp ($NASDAQ:MNKD)

MannKind Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics for diabetes and cancer. Its product pipeline includes Afrezza, MK-1293, and MK-3655. The company was founded by Alfred E. Mann on February 3, 1991 and is headquartered in Valencia, CA.

– Sanofi SA ($OTCPK:SNYNF)

Sanofi has a market cap of 98.97B as of 2022 and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and was founded in 1904. Sanofi is engaged in the research, development, manufacturing, and marketing of pharmaceutical products for the treatment of patients in the areas of cardiovascular, central nervous system, diabetes, internal medicine, oncology, and thrombosis.

– Eli Lilly and Co ($NYSE:LLY)

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

The company’s market cap is $312.67 billion as of 2022 and its return on equity is 45.88%.

Summary

United Therapeutics Corporation recently extended its licensing agreement with Eli Lilly, a major pharmaceutical company. This agreement gives United Therapeutics access to Lilly’s latest breakthroughs regarding treatments for lung fibrosis and other diseases. This move indicates a strong confidence in the research and development of United Therapeutics, a company focused on the development of treatments for cancer, pulmonary arterial hypertension (PAH), and other life-threatening conditions.

In addition, United Therapeutics has recently made investments in manufacturing capabilities, and is looking to expand its FDA-approved drug portfolio. Overall, this strategic move by United Therapeutics appears to be a strong signal that investors can expect positive returns on their investment in the company.